This website uses cookies. By using the site you are agreeing to our Privacy Policy.

HOME >> Investor Relations >> Top Message >> Message Archive (November 1, 2017)


To Our Investors

From November 1st, I am assuming the position of President and CEO of Japan Tissue Engineering Co., Ltd.,(J-TEC) and I would like to take this opportunity to greet all our stakeholders.

Ken-ichiro Hata
President & CEO Ken-ichiro Hata

I joined J-TEC in 2004, and since then I have been involved in the company’s research and development activities. I have had the privilege to take part in the marketing approval process of the autologous cultured epidermis JACE in 2009, and autologous cultured cartilage JACC in 2013, thanks to the great efforts of all the parts involved. More recently, during the revision of the laws governing regenerative medical products in our country, I have received even more support from all the parts concerned, and I deeply appreciate your cooperation.
Under these circumstances, J-TEC became part of the Fujifilm Group in 2014. Furthermore, in 2015, I became the General Manager of FUJIFILM’s Regenerative Medicine Research Laboratories, and last March, the General Manager of the Regenerative Medicine Business Division. During these past years, I was in an environment that allowed me to explore the possible synergies that could be created with FUJIFILM, and that helped me build the foundations of further growth for J-TEC.
In 2016, our previous CEO Aichiro Hiruma led the company to achieve profitability. In addition, he compared J-TEC’s management to a triple jump, in which the last fiscal year was the profitable “hop”, and this year represents the “step” to accelerate growth through the expansion of our businesses. Still following the policy to “dare to leap ahead” promoted by Mr. Hiruma, we will make our utmost efforts towards the company next “jump”.

In the second half of the current fiscal year, I would like to address the following points.

1. Further consolidation of regenerative medical products into medical treatment

Up to now, we have concentrated efforts to ensure that the autologous cultured epidermal JACE, and the autologous cultured cartilage JACC, would reach as many patients as fast as possible. Moreover, following the approval of an additional indication, JACE is now used not only to treat patients with extensive burns, but also children with Giant Congenital Melanocytic Nevus. However, we still need to increase awareness of regenerative medicine among the public and medical professionals. I believe that educating and delivering our products to patients who are in need of this medical care is our primary mission.

2. Enhance synergy with Fujifilm Group

The resources I was able to tap in my time within the Fujifilm Group are extremely important to further promote our business. High-performance material development technology, image analysis technology, and cell culture automation technology are indispensable for the future of regenerative medicine. Additionally, companies like Cellular Dynamics International and its iPS cell technology, and Wako Pure Chemicals and its know-how on cell culture media are also essential partners in the advancement of regenerative medicine. As someone who sees himself as a technologist, I will work to ensure these technological synergies blossom.

3. Educating the public

We will need to increase the number of people well-versed in regenerative medicine in order to accelerate its implementation, and create markets. Starting from J-TEC’s employees, we will strive to educate the public in regenerative medicine.

Finally, I sincerely thank all shareholders who have supported us day by day. Regenerative medicine has just reached an era of great advancement. As well as developing our businesses, I am committed to lead a company that will attend to the needs of both patients and their families. I greatly appreciate your continuous support.

November 1, 2017
Kenichiro Hata
President & CEO
Japan Tissue Engineering Co., Ltd.